Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.
Ka Lung
KL
Wu
Wessel
W
van Wieringen
Edo
E
Vellenga
Sonja
S
Zweegman
Henk M
HM
Lokhorst
Pieter
P
Sonneveld
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001897:Boronic Acids / Q000627:therapeutic use* / Q000633:toxicity*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D006562:Herpes Zoster / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D011719:Pyrazines / Q000627:therapeutic use* / Q000633:toxicity*; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib